Publication at Second Faculty of Medicine |
2008
Abstract
The BEAUTIFUL study has shown that even tho ugh mostly combined with beta blockers, ivabradine has reduced, in a statistically significant way, the need for hospitalisati on and for coronary revascularisati on due to fatal and non-fatal infarcti on in IHD pati ents with impaired left ventricular functi on and >= 70 be ats/ min baseline he art rate. It has also proven that he art rate is a significant prognostic sign in the monitored populati on of pati ents which deserves systematic attenti on.
Another important finding is the fact that ivabradine as a drug the effect of which is bo und to the capacity to reduce he art rate can be safely combined with beta blockers which still form part of the basic medicati on for IHD pati ents.